URGN
UroGen Pharma Ltd
41.20$
-1.0%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -7.9% | +12.5% | +40.5% | +7.1% | -5.4% | -13.3% | -15.7% | -11.3% | +8.3% | +26.6% | -0.4% | |
| – | -7.1% | +16.3% | +41.8% | +5.8% | -6.4% | -14.1% | -17.0% | -14.4% | +10.4% | +27.7% | -0.9% | |
| – | -19.7% | +38.0% | +66.3% | -43.2% | +37.7% | -39.5% | -10.7% | -3.1% | +23.0% | +0.5% | -28.9% | |
| – | -6.5% | +19.7% | +46.2% | +3.5% | -5.2% | -17.2% | -19.9% | -19.1% | -5.2% | +17.6% | -23.7% | |
| – | +20.2% | -8.3% | +23.0% | +30.9% | -11.0% | -3.3% | +0.1% | +0.3% | +67.9% | +67.5% | +60.2% | |
| – | +13.4% | +27.7% | +2.7% | +2.0% | +21.5% | -17.7% | -6.1% | +17.0% | +97.4% | +27.1% | +17.5% | |
| – | +3.4% | -1.2% | +4.5% | +9.9% | +6.5% | -0.1% | +2.7% | -0.5% | +1.8% | +23.5% | +1.9% | |
| – | +21.0% | -15.6% | +29.9% | -4.2% | +40.1% | -8.6% | +13.2% | -11.2% | +9.9% | +9.1% | +22.3% | |
| – | -4.5% | -4.9% | +104.4% | -48.2% | +270.9% | -53.8% | +9.5% | +2.6% | – | – | +9.3% | |
| – | +61.2% | -3.9% | +32.9% | -33.2% | +96.7% | +33.3% | -6.9% | -24.2% | +18.1% | +41.8% | +132.1% | |
| – | +0.0% | -1.0% | +0.2% | +24.4% | +0.0% | +0.3% | +0.3% | -0.3% | +0.1% | +55.1% | -0.4% | |
| – | – | – | – | -15.8% | -134.5% | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +11.9% | -7.7% | +10.3% | +17.1% | +9.1% | +0.8% | +0.7% | +0.7% | +2.4% | +1.9% | +0.4% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.